TAK-418 free base
Based on 2 publication(s) in Google Scholar
TAK-418 free base is an orally active, blood-brain barrier-penetrant LSD1 inhibitor with a human IC50 of 2.9 nM. TAK-418 free base irreversibly inhibits LSD1 by forming a compact flavin-FAD adduct with the catalytic domain FAD, blocking the demethylation of H3K4me1/2 and H3K9me1/2 without disrupting the LSD1-GFI1B interaction. TAK-418 free base restores normally dysregulated brain gene expression and DNA methylation, increases H3K4me1/2/3 and H3K9me2 at the Ucp2 locus, and induces Ucp2 mRNA expression. TAK-418 free base rescues defective H3K4 histone modifications, normalizes adult neurogenesis, and improves recognition memory, social behavior, and cognition in rodent models. TAK-418 free base can be used in research related to neurodevelopmental disorders, Alzheimer's disease, and autism spectrum disorders.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1818252-52-6
- Formule: C17H24N2O2S
- Masse moléculaire:320.45
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) TAK-418 free base
More
Activité biologique
Description
IC50 & Target
[2]|
LSD1 2.9 nM (IC50) |
In Vitro
TAK-418 (10 μM; 1 h) free base engages its cellular target LSD1 in TF-1a cells, as demonstrated by increased thermal stability of the protein[1].
TAK-418 free base is a specific inhibitor of LSD1 enzyme activity with an IC50 of 2.9 nM[2].
TAK-418 (40 min) free base inhibits LSD1 demethylase activity in the HTRF-based assay[2].
TAK-418 (1-3 days) free base increases histone methylation at the Ucp2 gene in primary cultured rat neurons[2].
TAK-418 (1-3 days) free base increases histone methylation at the Bdnf gene in primary cultured rat neurons[2].
TAK-418 (3 days) free base induces Ucp2 mRNA expression in primary cultured rat neurons[2].
TAK-418 free base has minimal impact on the LSD1-GFI1B interaction in TF-1a cells[2].
TAK-418 (1 mM; 1 h) free base forms a compact formylated FAD adduct in LSD1 protein[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:primary cultured rat neurons
-
Concentration:0.0001, 0.001, 0.01, 0.1, 1 and 10 μM
-
Incubation Time:3 days
-
Result:Increased H3K4me2 and H3K9me2 at the Ucp2 gene and induced Ucp2 mRNA expression.
Increased H3K4me1/2/3 at the Bdnf gene.
In Vivo
TAK-418 (1 mg/kg; p.o.; once daily; 14 days) free base does not improve memory, sociability, or sensorimotor gating deficits in miR-137 Tg mice[1].
TAK-418 (1 mg/kg; p.o.; once daily; 14 days) free base restores dysregulated gene expression and DNA methylation, and ameliorates social deficits and cognitive impairment in VPA (HY-10585)-induced ASD model rats[2].
TAK-418 (0.1-1 mg/kg; p.o.; once daily; 14 days) free base improves social behavior in poly I:C (HY-107202)-induced ASD model mice and restores dysregulated gene expression and DNA methylation to normal levels[2].
TAK-418 (1 mg/kg; p.o.; single administration or once daily for 14 days) free base does not affect cognitive function in normal healthy rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (aged male, 11-14 months old at purchase; 16 months old at testing)[1]
-
Dosage:0.1 or 0.3 mg/kg
-
Administration:p.o.; once daily; 4 days
-
Result:Improved recognition memory in aged mice, as assessed by the NOR test.
-
Animal Model:Tg2576 (female, 9 months old)[1]
-
Dosage:0.1 or 0.3 mg/kg
-
Administration:p.o.; once daily; 4 days
-
Result:Improved recognition memory deficits in Tg2576 mice at 0.3 mg/kg.
-
Animal Model:miR-137 transgenic (4 months old)[1]
-
Dosage:1 mg/kg
-
Administration:p.o.; once daily; 14 days
-
Result:Did not improve memory function in miR-137 Tg mice, as assessed by NOR tests.
Did not rescue sociability deficits or sensorimotor gating abnormalities.
-
Animal Model:Sprague-Dawley (SD) (male, juvenile and adult, maternal VPA exposure)[2]
-
Dosage:1 mg/kg
-
Administration:p.o.; once daily; 14 days (sociability, repetitive behavior, RNA-seq, ChIP-seq, RRBS); single administration (sociability); 1 week (sociability); 16-20 days (cognition)
-
Result:Showed 95.7% inhibition of LSD1 enzyme activity.
Completely recovered sociability in juvenile VPA rats at 1 mg/kg.
Completely recovered sociability in adult VPA rats at 1 mg/kg.
Recovered sociability in juvenile VPA rats after 1-week QD administration.
Significantly rescued decreased novelty discrimination index (NDI) in 6-week-old VPA rats after 16-20 days QD administration.
Observed inverse correlation between disease-induced changes and TAK-418 effects with correlation coefficients of -0.912 (juvenile) and -0.928 (adult).
Normalized dysregulated patterns of H3K9ac (correlation coefficient = -0.75) and DNA methylation (correlation coefficient = -0.90).
-
Animal Model:C57BL/6J (male, adult, maternal poly I:C exposure)[2]
-
Dosage:0.1-1 mg/kg
-
Administration:p.o.; QD; 14 days
-
Result:Showed 91.5% inhibition of LSD1 enzyme activity.
Significantly increased the sniffing index at 0.1, 0.3, or 1 mg/kg.
Observed inverse correlation between disease-induced changes and TAK-418 effects with a correlation coefficient of -0.958.
Normalized dysregulated patterns of DNA methylation with a correlation coefficient of -0.96.
-
Animal Model:Long-Evans (male, 7-week-old, naive)[2]
-
Dosage:1 mg/kg
-
Administration:p.o.; single administration or QD; 14 days
-
Result:Had no effects on delay-dependent forgetting of object memory.
Chemical Information
-
CAS No. 1818252-52-6
-
Masse moléculaire 320.45
-
Formule C17H24N2O2S
-
SMILES
O=C(NC1CCOCC1)C2=CSC([C@H](C3)[C@@H]3NCC4CC4)=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nature
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation. [Abstract]2025 Jun;642(8067):508-518. PMID: 40240608 -
Proc Natl Acad Sci U S A
2025 May 20;122(20):e2425812122. PMID: 40366693
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TAK-418 free base Related Classifications
HY-138830B Related Classifications
Powered by Bioz